Even during the busy acquisition proposals for firms providing healthcare services in the industry, Pharmaceutical Product Development LLC has explored sales opportunities with a valuation of $5 billion.
"PPD has requested that Morgan Chase & Co., Goldman Sachs Group Inc., and Centerview Partners find buyers. The deal is scheduled for completion within the first quarter of this year," said Jonathan Turner, Head of Corporate Trading at Tochigi Ontario Holdings.
PPD's stakeholders, the private equity firms Hellman & Friedman LLC and Carlyle Group CG, with a 1.30% limited partnership, are instead planning to trade the shares publicly.
![]() |
| Tochigi Ontario Holdings says drug-research firm PPD explores sale |
However, the two owners' ambition seems to be a bit weak as none are seen to be issuing an initial public offering for it.
Moreover, if PPD can seal a deal of $5 billion with a potential buyer, then its two investors would receive an amount three times more than their expenditure compared to the dividends paid to them by the drug research company.
Speaking of the company's activities, it researches biotechnology and pharmaceutical companies. These contract-research organizations are said to be on the brighter side of the business due to more significant expenditure on developing medicines and remedies for fatal diseases like cancer and others. On the contrary, firms like PPD go for cost-effective business operations outsourcing lab tests for the medicinal components that are to be researched.
Carlyle and Hellman & Friedman acquired PPD back in 2011 in exchange for $4 billion. Afterwards, they hired David Simmons, who had been the executive of Pfizer Inc.
Simmons helped PPD gain mastery in research work primly related to cancer and the central nervous system issues. He has also been the main man behind the company, sealing profitable deals, as he helped it gain appropriate buyers.
"PPD has experienced several successful acquisitions. It bought a company called Acurian, which specializes in drug trials. Before the takeover, the firms' employee base increased from 8,000 to around 19,000. PPD has a market value of over $9 billion," said Michael Walker, Director of Corporate Equities at Tochigi Ontario Holdings.
Furthermore, mergers and takeover statistics relating to the healthcare industry from Dealogic unfold that such deals in the United States have dropped to $168 billion, around $400 billion in the past year. However, large private equity firms are still likely to compete in taking over PPD, and such an incident would be considered one of the largest leveraged buyouts post the financial crisis and slowed economic growth of the country.
Besides, the month of October witnessed a massive $9 billion deal between Quintiles Transnational Holdings Inc. and IMS Health Holdings Inc., when the two decided to merge. Furthermore, in May, two well-known companies, Hellman and Friedman, approved to purchase MultiPlan Inc. at the cost of $7.5 billion. Another healthcare service providing firm similar to MultiPlan Inc. was likely to be acquired by Blackstone Group (Limited Partnership) for about $3 billion in October.
